covid_cell

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | July 1, 2020 | News story | Research and Development COVID-19, coronavirus 

COVID-19 vaccines dominate this week’s news cycle, with Vaxart announcing the selection of its lead candidate for COVID-19 by Operation Warp Speed, while China’s military have received approval to use a new vaccine candidate and AstraZeneca has continued to build its manufacturing capacity to deliver its coronavirus vaccine.

In other news, the National Institutes of Health had its funding cut from a research project into bat coronavirus while Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.

1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells CongressPublished 25/06/20

The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.

2. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnershipPublished 25/06/20

AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.

3. Vaxart announces its COVID-19 vaccine has been selected by US Operation Warp Speed programmePublished on 29/06/20

Vaxart has announced the selection of its lead vaccine candidate for COVID-19 by Operation Warp Speed, a program to find a vaccine for the US by the end of the year.

4. China’s COVID-19 vaccine candidate approved for military usePublished 29/06/20

China’s military have received approval to use a new vaccine candidate for coronavirus after clinical trials proved it was safe and showed some efficacy.

5. Gilead facing criticism for charging $2,340 for remdesivirPublished on 30/06/20

Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content